Navigation Links
Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board
Date:10/15/2009

MARKHAM, ON, Oct. 15 /PRNewswire/ - Cytochroma today announced that it has appointed John Cunningham, CVO, BM BCh, DM, FRCP, to the Company's Scientific Advisory Board.

Dr. Cunningham is Professor of Nephrology at the UCL Medical School, London and Consultant Nephrologist at the Royal Free Hospital, London. His early training was at Cambridge and Oxford Universities, with postgraduate training in The University of London and Washington University School of Medicine, St. Louis, USA. In 2005, he was appointed to the position of Physician to HM the Queen. Dr. Cunningham has extensive experience in the fields of hypertension, renal stone disease, acute and chronic kidney disease, renal transplantation and dialysis, and metabolic bone disease. He has published in excess of 100 peer reviewed scientific articles, is a visiting professor to various universities in Europe, Australia, and the United States, a member of numerous international expert panels and working groups, and a national and international lecturer.

"We are delighted and honored that Dr. Cunningham has agreed to advise Cytochroma on its efforts to develop new drugs for secondary hyperparathyroidism in chronic kidney disease patients," said Charles W. Bishop, Ph.D., President and Chief Executive Officer of Cytochroma. "Dr. Cunningham's wealth of knowledge and clinical experience will be invaluable as we move our products through mid- and late-stage clinical trials."

    Other members of Cytochroma's Scientific Advisory Board include:

    -   Geoff Block, MD - Director of Clinical Research, Denver Nephrology

    -   David Allen Bushinsky, MD - Professor of Medicine and of Pharmacology
        and Physiology, University of Rochester School of Medicine, and
        Chief, Nephrology Division, University of Rochester Medical Center

    -   Russell Chesney, MD - Le Bonheur Professor and Chair, Department of
        Pediatrics, University of Tennessee Health S
'/>"/>
SOURCE Cytochroma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cytochroma announces appointment of Ulrik Spork to Board of Directors
2. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
3. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma Appoints R. Richard Wieland II As CFO
6. Cytochroma opens U.S. headquarters in Illinois
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Sundia Appoints Charles D. Maher as Senior Vice President of Sales and Marketing
9. CalciMedica Appoints Evelyn Graham to its Board of Directors
10. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
11. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 LabStyle Innovations Corp. (OTCQB: DRIO), ... announced it recently closed a round of funding ... to support the global rollout and initial U.S. ... diabetes management solution that includes novel software applications ... monitoring device, and for working capital purposes. The ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... priority in the drug development approval process. Thus, innovator companies must understand what ... Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels and seminars ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
(Date:8/30/2015)... , August 31, 2015 ... einer Frau   für chirurgische   Behandlung     ... 7-90   werden für eine   verheerende   ... Frauen behandeln und die Anzahl ausgebildeter Chirurgen in Kenia ... Astellas gab heute bekannt, dass  Action on Fistula  seit ...
Breaking Biology Technology:LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... Engineering News (Volume 26, No. 11) , , ... one's own shop, even for a period longer than a year, ... filed later to protect the invention. , ,This rule was pronounced ... patent asserted that the patent was invalid due to prior public ...
... Wis. - A new combination of technical solutions ... publishing, broadcasting, and graphic design to transfer high-definition video ... joint solution promises Apple Mac OS X users in ... reduce the time demand for specialized data transfer tasks. ...
... the biotech industry? The July 2006 edition of MedAd News ... birthday this year. On Aug, 23, 2004, I wrote an article ... Boston, Geneva, or Chicago? " , ,In this article I reviewed ... that date the industry back to the 1970s and perhaps the ...
Cached Biology Technology:With patents and research tools, when is private really public? 2With patents and research tools, when is private really public? 3With patents and research tools, when is private really public? 4With patents and research tools, when is private really public? 5Small Tree branches out with affordable video 2At 30, biotech is an industry at a crossroads 2At 30, biotech is an industry at a crossroads 3At 30, biotech is an industry at a crossroads 4At 30, biotech is an industry at a crossroads 5At 30, biotech is an industry at a crossroads 6At 30, biotech is an industry at a crossroads 7
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... for centuries that copper is a potent weapon against ... serious urinary tract infections "know" this, too, and steal ... them. Blocking this thievery with a drug ... according to researchers at Washington University School of Medicine ...
... Calif.) An evaluation of national data by UC Davis researchers ... higher risk of death. When compared to those with ... risk of death during a follow-up period of six years. People ... if they also had diabetes or hypertension. The findings, ...
... be a breakthrough in the practical application of epigenetic ... that those with osteoarthritis have a signature epigenetic change ... gene that produces a destructive enzyme called MMP13. This ... destruction of joint cartilage, making MMP13 and the epigenetic ...
Cached Biology News:Urinary tract infections steal from hosts' defense arsenals 2UC Davis study finds that above-normal weight alone does not increase the short-term risk of death 2UC Davis study finds that above-normal weight alone does not increase the short-term risk of death 3Scientists discover an epigenetic cause of osteoarthritis 2
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Biology Products: